Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Open Label Study of Tipifarnib in Relapsed or Refractory Peripheral T-Cell Lymphoma
2016-001396-69Phase 2Active
- Sponsor
- Kura Oncology
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tipifarnib in peripheral T-cell lymphoma (PTCL), sponsored by Kura Oncology. Primary endpoints: Objective response rate, Progression-free survival and 1 more. Started Aug 2016; status: active.
02
Drugs
tipifarnib
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on 2016-001396-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001396-69.